Dr Niranjan MR @ NephroByte MD DM DNB

Associate Professor|Nephrologist|Mysore Medical College|Karnataka India. @Niranjan’s Health Care | Secretary |(MyNa)|Mysore Nephrology Association| Researcher

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

Snow White’s tale in nephrology: the emerging threat of skin-whitening creams on kidney health

https://t.co/sBnKiqyw4w

#Fairness #MGN #nephropearls

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

@arvindcanchi @ISNkidneycare @ISNeducation @ECNeph Even I got it 😊

[Grace Choung, MD 박영이 @grace_choung]

Complement in Kidney Disease: Core Curriculum 2026 - American Journal of Kidney Diseases https://t.co/C2hmAQQSFi

[Leonardo V. Riella @LVRiella]

Our latest study, just published in @TheLancet, reports the first successful transition from porcine kidney #xenotransplantation to human kidney transplantation.
A genetically engineered pig kidney provided >9 months (271 days) of dialysis-free kidney function before successful human transplantation, supporting xenotransplantation as a potential bridge while preserving future transplant options.
Beyond the clinical milestone, the study provides new insights into late microvascular inflammation and innate immune activation that will help shape future immunosuppressive strategies and donor genetic engineering.

Link to article: https://t.co/RCZFq2w5vD
@mgh_transplant @MGHSurgery @MGBResearchNews @MGBKidneys @eGenesisBio

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

Finerenone in Non Diabetic Kidney Disease

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

@NainsiDwiv50980 4.6

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

World Kidney Day 2026 Celebrations at Mysore Medical College and Research Institute, Mysore

[Ladan Zand @LadanZand]

In this article we show how the cancer incidence is higher in patients with PLA2R associated MN compared to general population- prostate cancer was one of the most common. Age appropriate cancer screening is essential in this group!

https://t.co/Z0Mo90u8Lf

[NDT @NDTsocial]

😩The updated global burden of chronic kidney disease:

one death every 20 seconds

🆓https://t.co/zlsw7IURNz

@ERAkidney @OxfordJournals

[JAMA @JAMA_current]

How can volume overload be reliably excluded at the bedside?

📊 This Rational Clinical Examination evaluates the diagnostic accuracy of clinical examination, radiographic imaging, and laboratory testing in assessing volume overload in nonintubated patients.

https://t.co/AkRpUEwfbJ

[Mala Sachdeva @mala_sachdeva]

FINE-ONE high impact clinical trial

[VR.Krishnakumar @KKNephBytes]

GLP1 Agonist in CKD #GLP-1A #CKD #Semaglutide @hardik4u24 @priti899 @nephromythri @yeshwanth_mohan

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

🎯 Prazosin: A Beacon of Hope for Nightmares in PTSD (Post-traumatic stress disorder)?

👉 Adrenergic hyperactivity begins at night, leading to increased responsiveness of alpha-1-adrenergic receptors, which promotes rapid eye movement (REM) sleep alteration, increases the frequency of nightmares in PTSD

👉 Prazosin is considered sufficiently lipophilic to cross the blood-brain barrier and antagonize the α1 receptors in the CNS, blocking the stress responses

👉 prazosin can improve sleep and reduce nightmares associated with PTSD

👉 Studies of a larger and more diverse patient population are further needed

Source: 1. https://t.co/hRdseugoli
2. https://t.co/JkAFobJduH

#prazosin #antihtn #alpha #PTSD #neph

[KDIGO @goKDIGO]

KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int.

Read the Guideline in KI: https://t.co/OvxwTGjjXx

Download the Executive Summary: https://t.co/WLJLwFnlZq

Read the News Release: https://t.co/gHZ1yvcuoe

Co-chaired by Dr. Jürgen Floege (DE) and @BradRovin, this update to the 2021 KDIGO Glomerular Diseases Guideline on IgAN incorporates evidence through August 2024. Given the rapid pace of discovery, KDIGO will continue to update the guideline regularly so clinicians and patients have access to the latest science and recommendations.

“This guideline represents a fundamental shift in how we approach IgA nephropathy,” said Dr. Floege. “For the first time, we can target both the immune mechanisms driving IgA injury and the kidney’s maladaptive responses. This dual strategy offers a roadmap to slow progression and extend kidney survival in ways not possible just a few years ago.”

“The science is moving faster than ever, and the treatment landscape has changed dramatically,” said Dr. Rovin. “With therapies like targeted-release budesonide, sparsentan, and SGLT2 inhibitors, we can intervene earlier and tailor care. We are moving from a single approach to a toolkit of therapies that can truly change outcomes for people around the world."

Download the Guideline: https://t.co/NUzPHXN4Zu

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

🎯 Managing Genital Mycotic Infections and UTIs Among patients on SGLT2i : Expert Consensus - A Quick Guide

Source: Gorgojo-Martínez et al A
Multidisciplinary Expert Consensus. J.
Clin. Med. 2024, 13, 6509. https://
https://t.co/UBfqatN4p9

#Nephpearls #UTI #SGLT2i #mycotic #infection

[CKJ @CKJsocial]

Ten tips to teach learners to love nephrology (and recruit the next generation)

https://t.co/YrS6UZUUYz

[NEJM @NEJM]

Original Article: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension (BaxHTN phase 3 trial) https://t.co/iRVxdmp7Ss

Editorial: Aldosterone Synthase Inhibition for Hypertension https://t.co/qAx3z4Iy7s

#ESCCongress | @escardio

[Billy Carson II @4biddnKnowledge]

A groundbreaking study from Wuhan University is turning everything we thought we knew about Parkinson’s disease upside down. Researchers now believe the disease may not start in the brain at all, but in the kidneys.

The study found abnormal clusters of alpha-synuclein (α-Syn) proteins, the same ones heavily linked to Parkinson’s, inside the kidneys of affected patients. These proteins are known to trigger neurological damage when they build up in the brain. However, in animal experiments, healthy kidneys successfully cleared these proteins. When kidney function was impaired, the α-Syn proteins began to travel to the brain, setting the stage for Parkinson’s.

Shockingly, even people with chronic kidney disease but no neurological symptoms were found to have α-Syn buildup. This discovery suggests the kidneys might act as an early “reservoir” for toxic proteins, which could later spread through the bloodstream or nerves and affect the brain.

Though early and based on limited data, this research could completely change how we understand and treat Parkinson’s. It raises the possibility that monitoring and protecting kidney health might one day help prevent or delay the onset of this devastating condition.

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

Occam's razor:

"Diagnostician should assume a single cause for multiple symptoms."

Hickam's dictum:

"A man can have as many diseases as he damn well pleases."

[Dr Niranjan MR @ NephroByte MD DM DNB @drniranjanmr2]

If I remember this patient he presented with AKI (Acute Gastroenteritis) on CKD, in fact he had Uremic frost as well!

[Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi]

@drniranjanmr2 @isn_india @ISNeducation @ECNeph Really high. My pt's creatinine was similar at 9.1
Makes you wonder about the high urea:creatinine ratio and wonder about the usual suspects 👇